Anixa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AB</div>
ANIX -- USA Stock  

USD 4.21  0.22  4.97%

Lets try to break down the odds of Anixa Biosciences to fully recover from the current slide as its shares went up 6.99%. This firm's current daily volatility is 5.43 percent, with a beta of 1.25 and an alpha of -0.23 over DOW. As many millenniums are trying to avoid pharmaceutical products, it makes sense to break down Anixa Biosciences a little further and try to understand its current market patterns. We will analyze why Anixa Biosciences investors may still consider a stake in the business.
Published over three months ago
View all stories for Anixa Biosciences | View All Stories
Is Anixa Biosciences (NASDAQ:ANIX) a new disruptor?
Anixa Biosciences currently holds about 5.51 M in cash with (5.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24. The firm shows a Beta (market volatility) of 1.2454, which signifies a somewhat significant risk relative to the market. Let's try to break down what Anixa's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Anixa Biosciences will likely underperform. Even though it is essential to pay attention to Anixa Biosciences historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Anixa Biosciences exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Anixa Biosciences has an expected return of -0.0199%. Please be advised to confirm Anixa Biosciences sortino ratio, as well as the relationship between the semi variance and rate of daily change to decide if Anixa Biosciences stock performance from the past will be repeated at some point in the near future.
Investing in Anixa Biosciences, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Anixa Biosciences along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Anixa Biosciences' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Anixa Biosciences in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Anixa Biosciences. Your research has to be compared to or analyzed against Anixa Biosciences' peers to derive any actionable benefits. When done correctly, Anixa Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Anixa Biosciences.

How important is Anixa Biosciences's Liquidity

Anixa Biosciences financial leverage refers to using borrowed capital as a funding source to finance Anixa Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Anixa Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Anixa Biosciences's total debt and its cash.

How Anixa utilizes its cash?

To perform a cash flow analysis of Anixa Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Anixa Biosciences is receiving and how much cash it distributes out in a given period. The Anixa Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Anixa Biosciences Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Net Cash Flow from Operations of (5.56 Million) in 2020

Anixa Biosciences Correlation with Peers

Investors in Anixa can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Anixa Biosciences. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Anixa Biosciences and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Anixa is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Anixa for more details

Acquisition by Michael Catelani of 100000 shares of Anixa Biosciences subject to Rule 16b-3

Legal trades by Anixa Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Anixa insider trading alert for grant of employee stock option (right to buy) by Michael Catelani, COO & CFO, on 28th of December 2020. This event was filed by Anixa Biosciences Inc with SEC on 2020-12-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Anixa Biosciences Indicators

Anixa Biosciences secures Sharpe Ratio (or Efficiency) of -0.0037, which signifies that the company had -0.0037% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Anixa Biosciences exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Anixa Biosciences risk adjusted performance of (0.001881), and Mean Deviation of 4.48 to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Anixa Biosciences implied volatility may change after the rise

Current Treynor Ratio is up to -0.05. Price may slide again. Anixa Biosciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Anixa Biosciences independently to ensure intended market timing strategies are aligned with expectations about Anixa Biosciences volatility.

The Bottom Line

While other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, Anixa Biosciences may offer a potential longer-term growth to investors. On the whole, as of the 11th of September 2020, our current 30 days buy vs. sell advice on the company is Cautious Hold. We believe Anixa Biosciences is currently undervalued with close to average probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Anixa Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to